Education of prostate MR imaging: commentary
AbstractMultiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
AbstractPurposeTo investigate and validate the potential role of a radiomics signature in predicting the side-specific probability of extracapsular extension (ECE) of prostate cancer (PCa).ProceduresThe preoperative magnetic resonance imaging data of 238 prostatic samples from 119 enrolled PCa patients were retrospectively assessed. The samples with were randomized in a two-to-one ratio into training (n = 74) and validation (n = 45) datasets. The radiomics features were derived from T2-weighted images (T2WIs). The optimal radiomics features were identified from the least absolute shrinkage and s...
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Publication date: Available online 25 May 2020Source: Practical Radiation OncologyAuthor(s): E. Ferrara, D. Beldì, J. Yin, L. Vigna, G. Loi, M. Krengli
Publication date: Available online 25 May 2020Source: Practical Radiation OncologyAuthor(s): Abhishek A. Solanki, Bital Savir-Baruch, Stanley L. Liauw, Jeff Michalski, Jonathan D. Tward, Neha Vapiwala, Eugene J. Teoh, Lee P. Adler, Gerald L. Andriole, Laurence H. Belkoff, Daniel Burzon, Albert Chau, Paul Dato, Fenghai Duan, Michael Farwell, Stephen Fogelson, Peter Gardiner, Lucy Hanna, John M. Hoffman, Charles Intenzo
In this study, we reported the heterogeneous activation of Wnt/β-catenin signaling in prostate cancer. We developed a Wnt/β-catenin signaling reporting system to directly characterize the differences between Wnt/β-catenin signaling active (GFP+) and inactive (GFP-) cells. Compared to GFP- cells, GFP+ cells demonstrated cancer stem cell properties with higher colony formation efficiency, slower cell cycle, higher resistance to docetaxel and higher expression of cancer stem cell markers. In addition, we found that Wnt/β-catenin signaling is negatively correlated with H3K27me3 levels. Further studies demon...
Are prostate cancer biopsies reliably accurate? Not always. The most common method, called a systematic biopsy, sometimes misses tumors, and it can also misclassify cancer as being either more or less aggressive than it really is. During systematic biopsy, a doctor takes 12 evenly-spaced samples of the prostate, called cores, while looking at the gland with an ultrasound machine. A new method, called MRI-targeted biopsy, guides doctors to suspicious abnormalities in the prostate, and emerging evidence suggests that it’s better at detecting high-grade, aggressive tumors that need immediate treatment. These biopsies re...
The expression of specific gene sets is associated with de novo enzalutamide resistance in men with metastatic castration-resistant prostate cancer, according to a new study.Reuters Health Information
CONCLUSION: A peritoneal flap after RARP was not found to influence the rate of postoperative lymphocele, whether asymptomatic or requiring treatment. PMID: 32449896 [PubMed - as supplied by publisher]
PROSTATE cancer symptoms can be difficult to spot during its early stages, but include passing more urine than normal, erectile dysfunction, and having a burning pain when using the toilet. But you could also be at risk of a tumour if your wee is one of three colours. Do you check your urine after using the toilet?
(Stand Up To Cancer) Olaparib, recently FDA-approved for patients with an aggressive form of prostate cancer, is a precision therapy that targets certain molecular qualities of advanced prostate cancer in patients with genetic mutations including BRCA1/2 who progressed despite prior treatment. The SU2C-PCF Dream Team research first demonstrated>20% metastatic prostate cancer patients have mutations including BRCA1/2, and>10% of these are inherited, leading to their clinical trials that tested olaparib as a potential treatment for these patients.